COMPANY INFO
Colossal Biosciences, Inc. is an American biotechnology and genetic engineering company founded in 2021 by Harvard geneticist George Church and serial entrepreneur Ben Lamm. The company, headquartered in Dallas, Texas, has around 170 employees and operates in the biotechnology industry with a focus on using CRISPR technology for de-extinction and conservation of extinct and endangered species. Their mission is to restore lost species such as the woolly mammoth, Tasmanian tiger, and dodo bird to their natural habitats, advancing both biodiversity and ecosystem health through innovative genetic engineering. The official website is colossal.com.
Colossal Biosciences Inc. is a pioneering American biotechnology and genetic engineering company founded in 2021 by Harvard geneticist George Church and entrepreneur Ben Lamm. Headquartered in Dallas, Texas with additional labs and partnerships across the United States and Australia, Colossal Biosciences Inc. is at the forefront of using CRISPR technology to pursue de-extinction and conservation of both extinct and endangered species. The company, with a team of around 170 employees, is dedicated to restoring species such as the woolly mammoth, Tasmanian tiger, and dodo bird to their natural habitats, thereby advancing biodiversity and ecosystem health through innovative genetic engineering solutions.
When it comes to Colossal Biosciences Inc. funding, the company has demonstrated an impressive trajectory, raising a total of $435 million across six funding rounds since its inception. Colossal Biosciences Inc. investors include leading names in venture capital, technology, and industry. Their fundraising strategy emphasizes both the scale and long-term vision of their ambitious projects, with key milestones including multiple oversubscribed rounds and a valuation now reaching $10.2 billion. The company’s blend of grant support, venture backing, and strategic partnerships has enabled accelerated technology development, team expansion, and the scaling of conservation efforts.
This latest round of funding is focused on advancing Colossal Biosciences Inc.'s genetic engineering technologies and expanding the company’s de-extinction species list. The Series C round solidified their Unicorn status, supporting further R&D and innovation in conservation genomics.
The venture round was dedicated to supporting ongoing research and development efforts, reinforcing Colossal Biosciences Inc.'s commitment to innovation in de-extinction science and technology.
Funding from this round was used to scale operations and further develop Colossal Biosciences Inc.'s de-extinction technologies, supporting key infrastructure investments and scientific milestones.
This grant supported specific research initiatives and technological advancements within Colossal Biosciences Inc., helping to drive progress in targeted areas of the company's scientific roadmap.
Series A funding enabled Colossal Biosciences Inc. to expand its interdisciplinary team and accelerate the development of proprietary genetic engineering technologies.
The seed round provided the initial capital for Colossal Biosciences Inc. to kickstart its groundbreaking de-extinction projects and establish its foundational research and development operations.
TWG Global is a leading global investment platform with a focus on transformative ventures. As a key Colossal Biosciences Inc. investor, TWG Global participated in the Series C round, providing critical capital to accelerate the company's technological and research ambitions.
Thomas Tull, a renowned entrepreneur and investor, has been an instrumental supporter of Colossal Biosciences Inc., leading the seed round and participating robustly in subsequent rounds. His involvement brings both financial resources and strategic expertise.
Tim Draper, a distinguished venture capitalist known for early investments in technology disruptors, is a prominent backer of Colossal Biosciences Inc., contributing both capital and industry insight.
Best-selling author and renowned business strategist Tony Robbins is an investor in Colossal Biosciences Inc., supporting the company’s vision with both funding and public exposure.
Winklevoss Capital Management, led by Cameron and Tyler Winklevoss, is a notable investor in Colossal Biosciences Inc., leveraging their experience in emerging technologies and venture capital to support the company’s growth.
Breyer Capital, a global venture capital and private equity firm, is among the key investors in Colossal Biosciences Inc., supplying expertise and growth capital for the company’s long-term mission.
Richard Garriott, famed entrepreneur and investor, is a backer of Colossal Biosciences Inc., supporting its groundbreaking efforts to merge science, technology, and conservation.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Colossal Biosciences Inc. funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.